Published in ISRN Urol on July 17, 2012
Andrographolide inhibits the activation of NF-κB and MMP-9 activity in H3255 lung cancer cells. Exp Ther Med (2013) 0.78
Urinary Bladder Cancer: Biomarkers and Target Therapy, New Era for More Attention. Oncol Rev (2016) 0.75
Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes protein O-glycosylation extension. Oncotarget (2016) 0.75
Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior. Sci Rep (2017) 0.75
Weight loss surgery improves the metabolic status in an obese rat model but does not affect bladder fibrosis associated with high fat diet feeding. Int J Obes (Lond) (2013) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol (2001) 14.05
MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell (1998) 9.70
Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol (2002) 5.73
Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer (2002) 5.57
Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer (2005) 4.80
Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci (2002) 4.23
Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression. J Cell Biol (1994) 3.68
Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest (1999) 3.35
Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. J Biol Chem (1990) 3.25
CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev (2002) 2.35
Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer (2006) 2.20
Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature (1997) 2.17
Matrix metalloproteinases in tumor-host cell communication. Differentiation (2002) 2.16
Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res (2001) 2.12
Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res (1993) 1.97
Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate. Biochemistry (1990) 1.91
Regulation of matrix metalloproteinase activity in health and disease. FEBS J (2010) 1.88
Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett (2000) 1.72
Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eur Urol (2007) 1.66
Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer (1998) 1.65
Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin Cancer Res (2000) 1.60
The contradictions of the insulin-like growth factor 1 receptor. Oncogene (2000) 1.52
Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human urothelial carcinomas. J Urol (1998) 1.48
Structural properties of matrix metalloproteinases. Cell Mol Life Sci (1999) 1.43
[Detection and molecular staging of bladder cancer using real-time RT-PCR for gelatinases (MMP-2, MMP-9) and TIMP-2 in peripheral blood]. Actas Urol Esp (2011) 1.40
Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors. Nat Struct Biol (1999) 1.40
Membrane type-matrix metalloproteinases (MT-MMP). Curr Top Dev Biol (2003) 1.39
Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res (2005) 1.36
Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia (2002) 1.33
Occupation and bladder cancer in a hospital-based case-control study in Spain. Occup Environ Med (2007) 1.32
Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. Exp Cell Res (2005) 1.30
Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival. Acta Oncol (2010) 1.28
Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer (1998) 1.27
Quantification of matrix metalloproteinases in tissue samples. Methods Enzymol (1995) 1.24
Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res (2002) 1.24
Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis. Cancer Res (1995) 1.18
Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer. BJU Int (2010) 1.17
Requirement for matrix metalloproteinase stromelysin-3 in cell migration and apoptosis during tissue remodeling in Xenopus laevis. J Cell Biol (2000) 1.15
Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells. Oncogene (2004) 1.14
4-aminobiphenyl is a major etiological agent of human bladder cancer: evidence from its DNA binding spectrum in human p53 gene. Carcinogenesis (2002) 1.12
High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Cancer Res (2001) 1.08
Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis (2005) 1.08
Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer. J Urol (2007) 1.06
High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res (1996) 1.05
Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology (2001) 1.05
Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer. Cancer Sci (2010) 1.05
Metastatic bladder cancer. Natural history, clinical course, and consideration for treatment. Urol Clin North Am (1992) 1.00
Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12. J Mol Biol (2004) 1.00
Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer. Anticancer Res (2000) 0.98
Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer (1996) 0.95
Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res (1996) 0.95
Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumours. Br J Cancer (1998) 0.93
Enhanced detection of casein zymography of matrix metalloproteinases. Anal Biochem (1995) 0.90
Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer. Pathol Oncol Res (2011) 0.89
Dermatological aspects of angiogenesis. Br J Dermatol (2002) 0.88
Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer. Clin Biochem (2007) 0.87
Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors. Oncol Rep (2006) 0.87
Structural basis of matrix metalloproteinase function. Biochem Soc Symp (2003) 0.85
A single-nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances bladder cancer susceptibility. BJU Int (2007) 0.85
Ras oncogene mutations in urine sediments of patients with bladder cancer. J Biochem Mol Biol (2003) 0.85
Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer. Br J Cancer (1998) 0.84
Strong correlation of basement membrane degradation with p53 inactivation and/or MDM2 overexpression in superficial urothelial carcinomas. J Urol (1997) 0.79
Significance of collagenase 3 (matrix metalloproteinase 13) in invasive bladder cancer: correlation with pathological parameters. Urol Int (2007) 0.79
Low circulating levels of ProMMP-2 are associated with adverse prognosis in bladder cancer. Tumour Biol (2008) 0.78
Serum levels of a tissue inhibitor of metalloproteinases-1 (TIMP-1) in bladder cancer patients. Int J Urol (1994) 0.78
Methods for studying activation of matrix metalloproteinases. Methods Mol Biol (2010) 0.77
Levels of tissue inhibitor of metalloproteinases 1 in plasma and urine from patients with bladder cancer. Int J Biol Markers (2006) 0.76
Prognostic value of membrane type 1 and 2 matrix metalloproteinase expression and gelatinase A activity in bladder cancer. Int J Biol Markers (2010) 0.76
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 2.65
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 2.53
Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol (2000) 2.38
TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer (1997) 1.80
Liver expression of matrix metalloproteases and their inhibitors in hepatocellular carcinoma. Dig Liver Dis (2009) 1.50
Metastatic tumor of the epididymis and spermatic cord. Eur Urol (1983) 1.50
Duodenal expression of Toll-like receptors and interleukins are increased in both children and adult celiac patients. Dig Dis Sci (2012) 1.45
[A new approach to urinary stone analysis according to the combination of the components: experience with 7949 cases]. Actas Urol Esp (2011) 1.40
Prevention of vesicoureteral reflux at the time of complete primary repair of the exstrophy-epispadias complex. Int Urol Nephrol (2004) 1.40
[Early diagnosis of prostatic cancer: state of the art]. Med Clin (Barc) (1994) 1.39
[Combined approach of laparoscopic and open surgery for complex renal lesions]. Actas Urol Esp (2012) 1.39
[Renal retransplantation: risk factors and results]. Actas Urol Esp (2011) 1.38
[Squamous cell carcinoma of the penis: treatment protocol according to our 14 years of experience]. Arch Esp Urol (1997) 1.37
Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br J Cancer (2007) 1.27
Staging of early prostate cancer: a proposed tumor volume-based prognostic index. Urology (1993) 1.20
EAU Guidelines on Penile Cancer. Eur Urol (2004) 1.19
[EAU guidelines on testicular cancer: 2011 update. European Association of Urology]. Actas Urol Esp (2011) 1.19
Small cell carcinoma of the urinary bladder. Presentation of 23 cases and review of 134 published cases. Eur Urol (2001) 1.11
Grade, local stage and growth pattern as prognostic factors in carcinoma of the penis. Eur Urol (1997) 1.06
Morphological identification of the patterns of prostatic intraepithelial neoplasia and their importance. J Clin Pathol (2000) 1.02
Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol (2005) 0.99
High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment. World J Urol (2012) 0.97
Cutaneous metastases in renal cell carcinoma. Urol Int (2008) 0.97
Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumor stromal fibroblasts and those at the invasive front of breast carcinomas. Breast Cancer Res Treat (2009) 0.96
Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol (2000) 0.94
Balanitis xerotica obliterans in children. J Urol (1986) 0.92
Growing teratoma syndrome: experience of a single institution. Eur Urol (1997) 0.90
Nephron-sparing surgery for renal tumor: a choice of treatment in an allograft kidney. Transplant Proc (2006) 0.89
It's like a pain in the ... perineum: a surgical clip protruding into the urethra through the urethrovesical anastomosis after radical prostatectomy. Scand J Urol Nephrol (1997) 0.89
Percutaneous management of transplant ureteral fistulae is feasible in selected cases. Transplant Proc (2005) 0.88
Quality-of-life assessment in patients with benign prostatic hyperplasia: effects of various interventions. Pharmacoeconomics (2001) 0.88
Variation in reporting of cancer extent and benign histology in prostate biopsies among European pathologists. Virchows Arch (2014) 0.87
The use of mannitol in partial and live donor nephrectomy: an international survey. World J Urol (2012) 0.85
[Testicular tumours in infancy and children]. Actas Urol Esp (2011) 0.85
Expression of metalloproteases and their inhibitors in different histological types of breast cancer. J Cancer Res Clin Oncol (2009) 0.85
Testicular pseudolymphoma. Eur Urol (1986) 0.85
Fournier's gangrene: a monographic urology center experience with twenty patients. Urol Int (2009) 0.83
Significance of ureteral carcinoma in situ in specimens of cystectomy. Eur Urol (1994) 0.83
Handling and reporting of radical prostatectomy specimens in Europe: a web-based survey by the European Network of Uropathology (ENUP). Histopathology (2008) 0.83
[Simultaneous bilateral testicular tumors]. Actas Urol Esp (1990) 0.82
Follow-up of the remaining bladder after supravesical urinary diversion. Eur Urol (1996) 0.82
Endourological management is better in early-onset ureteral stenosis in kidney transplantation. Transplant Proc (2005) 0.82
Clamping of the renal artery in laparoscopic partial nephrectomy: an old device for a new technique. Eur Urol (2005) 0.82
Hepatocarcinoma and oral contraceptives. Lancet (1978) 0.82
Precancerous lesions in the kidney. Scand J Urol Nephrol Suppl (2000) 0.81
Clear cell adenocarcinoma in a female urethral diverticulum. Scand J Urol Nephrol (2000) 0.81
Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast. Histopathology (2007) 0.81
Treatment of transitional cell carcinoma of the ureter: is the controversy justified? Eur Urol (1990) 0.81
Consensus statement on terminology: recommendation to use atypical adenomatous hyperplasia in place of adenosis of the prostate. Am J Surg Pathol (1994) 0.81
Staghorn renal stone in a transplanted kidney. Urol Int (1990) 0.81
Molecular staging of bladder cancer with RT-PCR assay for CK20 in peripheral blood, bone marrow and lymph nodes: comparison with standard histological staging. Anticancer Res (2006) 0.80
Predictive factors for impaired renal function following nephroureterectomy in upper urinary tract urothelial cell carcinoma. Urol Int (2013) 0.80
[A second transurethral resection could be not necessary in all high grade non-muscle-invasive bladder tumors]. Actas Urol Esp (2012) 0.80
What is the added value of combined core biopsy and fine needle aspiration in the diagnostic process of renal tumours? World J Urol (2011) 0.80
A simplified technique for ureteroneocystostomy in renal transplantation. World J Urol (1996) 0.79
Transitional cell carcinoma of the prostate. Eur Urol (1985) 0.79
Study of matrix metalloproteinases and their inhibitors in prostate cancer. Br J Cancer (2010) 0.79
Altered gene expression signature of early stages of the germ line supports the pre-meiotic origin of human spermatogenic failure. Andrology (2014) 0.79
[EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update]. Actas Urol Esp (2012) 0.79
Re: Comparison of hand assisted and standard laparoscopic radical nephroureterectomy for the management of localized transitional cell carcinoma. J Urol (2004) 0.79
Intraepithelial lesions of urinary bladder: morphologic considerations. Scand J Urol Nephrol Suppl (2000) 0.79
Desmoplastic small round-cell tumor. Am J Surg Pathol (1992) 0.79
Preservation of renal function in a patient with Fabry nephropathy on enzyme replacement therapy. Clin Nephrol (2008) 0.78
Bladder blood flow and de-obstructive open prostatectomy: correlation with clinical and urodynamic parameters. Int Urol Nephrol (2005) 0.78
EAU guidelines on testicular cancer. Eur Urol (2001) 0.77
[Should hernioplasty be combined with surgery of the prostate?]. Arch Esp Urol (1998) 0.77
[Skin metastasis during follow-up of a clear cell renal carcinoma]. Arch Esp Urol (2008) 0.77
Treatment of stage I testicular tumours. Br J Urol (1993) 0.77
[National prostate cancer registry 2010 in Spain]. Actas Urol Esp (2012) 0.77
Preoperatively recognized chronically retained pararenal gauzoma. Int Urol Nephrol (1995) 0.77
Management and prognosis of transitional cell carcinoma superficial recurrence in muscle-invasive bladder cancer after bladder preservation. Eur Urol (2003) 0.77
Primary bladder carcinoma in situ: assessment of early BCG response as a prognostic factor. Eur Urol (1998) 0.77
Intensive chemotherapy in poor-prognosis nonseminomatous germ cell tumors of the testis. Eur Urol (1992) 0.77
Prognostic value of cystocopically pseudotumoral lesions (inflammation/granuloma) in primary stage T1 grade 3 bladder tumors treated with BCG. Int Urol Nephrol (2001) 0.77
[Cystitis glandularis]. Arch Esp Urol (1999) 0.76
The role of repeat transurethral resection in stage A1 carcinoma of the prostate. Eur Urol (1989) 0.76
Origin of high-grade superficial bladder cancer. Eur Urol (1987) 0.76
Histological evaluation of superficial bladder tumors treated by Nd-YAG laser and transurethral resection. Eur Urol (1991) 0.76
Meconium vaginalitis. Br J Urol (1991) 0.76
Large cell calcifying Sertoli cell tumour of the testis. Histopathology (1995) 0.76
Upper tract urothelial tumor after transurethral resection for bladder tumor. Eur Urol (1992) 0.76
Fibrous polyp of the ureter. Eur Urol (1981) 0.76
Report of the Committee on Staging and Pathology. Cancer (1992) 0.75
[Neurocysticercosis and convulsive crises]. Rev Neurol (1998) 0.75
[Comments to the article «robotic surgery: history and impact on teaching»]. Actas Urol Esp (2012) 0.75
[The physiopathology and management of sexual dysfunction in epileptic patients]. Rev Neurol (2008) 0.75
Expression and clinical significance of pepsinogen C in uveal melanomas. Int J Biol Markers (2004) 0.75
Treatment of non muscle invasive bladder tumor related to the problem of bacillus Calmette-Guerin availability. Consensus of a Spanish expert's panel. Spanish Association of Urology. Actas Urol Esp (2013) 0.75
[Surgical aspects of living donor nephrectomy]. Actas Urol Esp (2012) 0.75
[Relevance of the clinical-pathological predictive factors in force in chromophobe renal cell cancer]. Actas Urol Esp (2012) 0.75
Autopsy study of liver cell carcinoma in Barcelona, Spain. Pathol Annu (1976) 0.75